Cellular Origins appoints Geoffrey Hodge as Non-Executive Director

FHS
July 16, 2024
10:37 am

Appointment brings additional significant strategic, technical and commercial experience to the Board.

Single-cell study reveals clues to epigenetic drug response in Myelodysplastic Syndrome

Researchers from the Josep Carreras Leukaemia Research Institute, spearheaded by the Cancer Epigenetics group led by Dr. Manel Esteller, described the effects of chemotherapy at

February 6, 2024

Gilead’s Vemlidy expands label to treat paediatric chronic HBV – Pharmaceutical Technology

Share this article Vemlidy is approved to treat patients six years and older for chronic HBV. Credits: Sundry Photography/Shutterstock.com Soon after GSK gained traction with

April 1, 2024

GLP-1 drugs are transforming diabetes, obesity and more. Could a Nobel be next?

Next week, 50 medical experts from the Karolinska Institutet in Stockholm will meet to award the 2023 Nobel Prize for Physiology or Medicine. The vote

September 30, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.